{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:03:11Z","timestamp":1792144991200,"version":"4.4.0"},"reference-count":125,"publisher":"Japan Academy","issue":"2","funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP19K08850"],"award-info":[{"award-number":["JP19K08850"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Proc. Jpn. Acad., Ser. B","Proceedings of the Japan Academy. Ser. B: Physical and Biological Sciences"],"published-print":{"date-parts":[[2025]]},"DOI":"10.2183\/pjab.101.006","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T17:11:22Z","timestamp":1734455482000},"page":"75-97","source":"Crossref","is-referenced-by-count":24,"title":["Thrombomodulin: A key regulator of intravascular blood coagulation, fibrinolysis, and inflammation, and a treatment for disseminated intravascular coagulation"],"prefix":"10.2183","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6672-8833","authenticated-orcid":false,"given":"Koji","family":"SUZUKI","sequence":"first","affiliation":[{"name":"Professor, Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie, Japan."},{"name":"Vice President for Research, Suzuka University of Medical Science, Suzuka, Mie, Japan."},{"name":"Professor Emeritus, Mie University, Tsu, Mie, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"993","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Stenflo, J. (1976) A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization. J. Biol. Chem. <b>251<\/b>, 355-363.","DOI":"10.1016\/S0021-9258(17)33886-3"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Suzuki, K., Stenflo, J., Dahlb\u00e4ck, B. and Teodorsson, B. (1983) Inactivation of human coagulation factor V by activated protein C. J. Biol. Chem. <b>258<\/b>, 1914-1920.","DOI":"10.1016\/S0021-9258(18)33076-X"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Esmon, C.T. and Owen, W.G. (1981) Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc. Natl. Acad. Sci. U.S.A. <b>78<\/b>, 2249-2252.","DOI":"10.1073\/pnas.78.4.2249"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Esmon, N.L., Owen, W.G. and Esmon, C.T. (1982) Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J. Biol. Chem. <b>257<\/b>, 859-864.","DOI":"10.1016\/S0021-9258(19)68276-1"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Salem, H.H., Maruyama, I. Ishii, H. and Majerus, P.W. (1984) Isolation and characterization of thrombomodulin from human placenta. J. Biol. Chem. <b>259<\/b>, 12246-12251.","DOI":"10.1016\/S0021-9258(20)71346-3"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Maruyama, I., Bell, C.E. and Majerus, P.W. (1985) Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. J. Cell Biol. <b>101<\/b>, 363-371.","DOI":"10.1083\/jcb.101.2.363"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Suzuki, K., Nishioka, J., Hayashi, T. and Kosaka Y. (1988) Functionally active thrombomodulin is present in human platelets. J. Biochem. <b>104<\/b>, 628-632.","DOI":"10.1093\/oxfordjournals.jbchem.a122523"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Wong, V. L., Hofman, F. M., Ishii, H. and Fisher, M. (1991) Regional distribution of thrombomodulin in human brain. Brain Res. <b>556<\/b>, 1-5.","DOI":"10.1016\/0006-8993(91)90540-C"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Mizutani, H., Ohyanagi, S., Hayashi, T., Groves, R.W., Suzuki, K. and Shimizu, M. (1996) Functional thrombomodulin expression on epithelial skin tumours as a differential marker for suprabasal keratinocytes. Br. J. Dermatol. <b>135<\/b>, 187-193.","DOI":"10.1046\/j.1365-2133.1996.d01-973.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Alonso, F., Dong, Y. and G\u00e9not, E. (2021) Thrombomodulin, an unexpected new player in endothelial cell invasion during angiogenesis. Arterioscler. Thromb. Vasc. Biol. <b>41<\/b>, 1672-1674.","DOI":"10.1161\/ATVBAHA.121.316205"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Wu, C.T., Chang, Y.H., Chen, W.C. and Chen, M.F. (2014) Thrombomodulin expression regulates tumorigenesis in bladder cancer. BMC Cancer <b>14<\/b>, 375.","DOI":"10.1186\/1471-2407-14-375"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Okamoto, T., Hattori, M., Katsube, Y., Ohta, J., Asanuma, K., Usuda, H. <i>et al<\/i>. (2025) Hornerin expressed on endothelial cells via interacting with thrombomodulin modulates vascular inflammation and angiogenesis. Biochim. Biophys. Acta Mol. Cell Res. <b>1872<\/b>, 119891.","DOI":"10.1016\/j.bbamcr.2024.119891"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Tazawa, R., Hirosawa, S., Suzuki, K., Hirokawa, K. and Aoki, N. (1993) Functional characterization of the 5\u2032-regulatory region of the human thrombomodulin gene. J. Biochem. <b>113<\/b>, 600-606.","DOI":"10.1093\/oxfordjournals.jbchem.a124089"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Boon, R. A. and Horrevoets, A.J. (2009) Key transcriptional regulators of the vasoprotective effects of shear stress. Hamostaseologie <b>29<\/b>, 39-43.","DOI":"10.1055\/s-0037-1616937"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Zhang, G., Qin, Q., Zhang, C., Sun, X., Kazama, K., Yi, B. <i>et al.<\/i> (2023) NDRG1 signaling is essential for endothelial inflammation and vascular remodeling. Circ. Res. <b>132<\/b>, 306-319.","DOI":"10.1161\/CIRCRESAHA.122.321837"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Hayashi, T., Honda, G. and Suzuki, K. (1992) An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein cells. Blood <b>79<\/b>, 2930-2936.","DOI":"10.1182\/blood.V79.11.2930.bloodjournal79112930"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Saito, Y., Wada, H., Yamamuro, M., Inoue, A., Shimura, M., Hiyoyama, K. <i>et al<\/i>. (1999) Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease. Am. J. Hematol. <b>61<\/b>, 238-242.","DOI":"10.1002\/(SICI)1096-8652(199908)61:4<238::AID-AJH3>3.3.CO;2-#"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Sapru, A., Calfee, C.S., Liu, K.D., Kangelaris, K., Hansen, H., Pawlikowska, L. <i>et al.<\/i> (2015) Plasma soluble thrombomodulin levels are associated with mortality in the acute respiratory distress syndrome. Intensive Care Med. <b>41<\/b>, 470-478.","DOI":"10.1007\/s00134-015-3648-x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Takeda, N., Maemura, K., Horie, S., Oishi, K., Imai, Y., Harada, T. <i>et al<\/i>. (2007) Thrombomodulin is a clock-controlled gene in vascular endothelial cells. J. Biol. Chem. <b>282<\/b>, 32561-32567.","DOI":"10.1074\/jbc.M705692200"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Suzuki, K., Kusumoto, H., Deyashiki, Y., Nishioka, J., Maruyama, I., Zushi, M. <i>et al<\/i>. (1987) Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J. <b>6<\/b>, 1891-1897.","DOI":"10.1002\/j.1460-2075.1987.tb02448.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Shirai, T., Shiojiri, S., Ito, H., Yamamoto, S., Kusumoto, H. <i>et al.<\/i> (1988) Gene structure of human thrombomodulin, a cofactor for thrombin-catalyzed activation of protein C. J. Biochem. <b>103<\/b>, 281-285.","DOI":"10.1093\/oxfordjournals.jbchem.a122261"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Suzuki, K., Hayashi, T., Nishioka, J., Kosaka, Y., Zushi, M., Honda, G. <i>et al.<\/i> (1989) A domain composed of epidermal growth factor-like structures of human thrombomodulin is essential for thrombin binding and for protein C activation. J. Biol. Chem. <b>264<\/b>, 4872-4876.","DOI":"10.1016\/S0021-9258(18)83672-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Zushi, M., Gomi, K., Yamamoto, S., Maruyama, I., Hayashi, T. and Suzuki, K. (1989) The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and antithrombin activity. J. Biol. Chem. <b>264<\/b>, 10351-10353.","DOI":"10.1016\/S0021-9258(18)81626-X"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Suzuki, K., Nishioka, J. and Hayashi, T. (1990) Localization of thrombomodulin- binding site within human thrombin. J. Biol. Chem. <b>265<\/b>, 13263-13267.","DOI":"10.1016\/S0021-9258(19)38293-6"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Suzuki, K. and Nishioka, J. (1991) A thrombin-based peptide corresponding to the sequence of the thrombomodulin-binding site blocks the procoagulant activities of thrombin. J. Biol. Chem. <b>266<\/b>, 18498-18501.","DOI":"10.1016\/S0021-9258(18)55088-2"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Tsiang, M., Jain, A.K., Dunn, K.E., Rojas, M.E., Leung, L.L. and Gibbs, C.S. (1995) Functional mapping of the surface residues of human thrombin. J. Biol. Chem. <b>270<\/b>, 16854-16863.","DOI":"10.1074\/jbc.270.28.16854"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Suzuki, K. and Kamimura, M. (1999) Thrombin: Structure-function relationship. Jpn. J. Thromb. Hemost. <b>10<\/b>, 195-203 (in Japanese).","DOI":"10.2491\/jjsth.10.195"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Fuentes-Prior, P., Iwanaga, Y., Huber, R., Pagila, R., Rumennik, G., Seto, M. <i>et al.<\/i> (2000) Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature <b>404<\/b>, 518-525.","DOI":"10.1038\/35006683"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Okada, M., Tominaga, N., Honda, G., Nishioka, J., Akita, N., Hayashi, T. <i>et al<\/i>. (2020) A case of thrombomodulin mutation causing defective thrombin binding with absence of protein C and TAFI activation. Blood Adv. <b>4<\/b>, 2631-2639.","DOI":"10.1182\/bloodadvances.2019001155"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Urano, T., Sano, Y., Suzuki, Y., Okada, M., Sano, H., Honkura, N. <i>et al.<\/i> (2024) Evaluation of thrombomodulin\/thrombin activatable fibrinolysis inhibitor function in plasma using tissue-type plasminogen activator-induced plasma clot lysis time. Res. Pract. Thromb. Haemost. <b>8<\/b>, 102463.","DOI":"10.1016\/j.rpth.2024.102463"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Ye, J., Esmon, C.T. and Johnson, A.E. (1993) The chondroitin sulfate moiety of thrombomodulin binds a second molecule of thrombin. J. Biol. Chem. <b>268<\/b>, 2373-2379.","DOI":"10.1016\/S0021-9258(18)53786-8"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Delvaeye, M., Noris, M., De Vriese, A., Esmon, C.T., Esmon, N.L., Ferrell, G. <i>et al<\/i>. (2009) Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N. Engl. J. Med. <b>361<\/b>, 345-357.","DOI":"10.1056\/NEJMoa0810739"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Healy, A.M., Rayburn, H.B., Rosenberg, R.D. and Weiler, H. (1995) Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc. Natl. Acad. Sci. U.S.A. <b>92<\/b>, 850-854.","DOI":"10.1073\/pnas.92.3.850"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Gu, J.M., Crawley, J.T., Ferrell, G., Zhang, F., Li, W., Esmon, N.L. <i>et al<\/i>. (2002) Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality. J. Biol. Chem. <b>277<\/b>, 43335-43343.","DOI":"10.1074\/jbc.M207538200"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Zushi, M., Gomi, K., Honda, G., Kondo, S., Yamamoto, S., Hayashi, T. <i>et al<\/i>. (1991) Aspartic acid 349 in the fourth epidermal growth factor-like structure of human thrombomodulin plays a role in its Ca<sup>2\uff0b<\/sup>-mediated binding to protein C. J. Biol. Chem. <b>266<\/b>, 19886-19889.","DOI":"10.1016\/S0021-9258(18)54865-1"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Stearns-Kurosawa, D.J., Kurosawa, S., Mollica, J.S., Ferrell, G.L. and Esmon, C.T. (1996) The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc. Natl. Acad. Sci. U.S.A. <b>93<\/b>, 10212-10216.","DOI":"10.1073\/pnas.93.19.10212"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Slungaard, A. (2004) Platelet factor 4 modulation of the thrombomodulin-protein C system. Crit. Care Med. <b>32<\/b>, S331-S335.","DOI":"10.1097\/01.CCM.0000126359.92825.E9"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Walker, F.J. (I981) Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. J. Biol. Chem. <b>256<\/b>, 11128-11131.","DOI":"10.1016\/S0021-9258(19)68566-2"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Suzuki, K., Nishioka, J., Matsuda, M., Murayama, H. and Hashimoto, S. (1984) Protein S is essential for activated protein C-catalyzed inactivation of platelet-associated Factor Va. J. Biochem. <b>96<\/b>, 455-495.","DOI":"10.1093\/oxfordjournals.jbchem.a134857"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Rezende, S.M., Simmonds, R.E. and Lane, D.A. (2004) Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex. Blood <b>103<\/b>, 1192-1201.","DOI":"10.1182\/blood-2003-05-1551"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Hillarp, A., Thern, A. and Dahlb\u00e4ck, B. (1994) Bovine C4b binding protein. Molecular cloning of the alpha- and beta-chains provides structural background for lack of complex formation with protein S. J. Immunol. <b>153<\/b>, 4190-4199.","DOI":"10.4049\/jimmunol.153.9.4190"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Hackeng, T.M., Ser\u00e9, K.M., Tans, G. and Rosing, J. (2006) Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc. Natl. Acad. Sci. U.S.A. <b>103<\/b>, 3106-3111.","DOI":"10.1073\/pnas.0504240103"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) M\u00fcller, F.M., Ehrenthal, W., Hafner, G. and Schranz, D. (1996) Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate. Eur. J. Pediatr. <b>155<\/b>, 20-25.","DOI":"10.1007\/BF02115621"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Ido, M., Ohiwa, M., Hayashi, T., Nishioka, J., Hatada, T., Watanabe, H. <i>et al<\/i>. (1993) A compound heterozygous protein C deficiency with a single nucleotide G deletion encoding Gly-381 and an amino acid substitution of Lys for Gla-26. Thromb. Haemost. <b>70<\/b>, 636-641.","DOI":"10.1055\/s-0038-1649641"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Jalbert, L.R., Rosen, E.D., Moons, L., Chan, J.C., Carmeliet, P., Collen, D. <i>et al<\/i>. (1998) Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J. Clin. Invest. <b>102<\/b>, 1481-1488.","DOI":"10.1172\/JCI3011"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Marlar, R.A. and Neumann, A. (1990) Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin. Thromb. Hemost. <b>16<\/b>, 299-309.","DOI":"10.1055\/s-2007-1002683"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Hayashi, T., Nishioka, J., Shigekiyo, T., Saito, S. and Suzuki, K. (1994) Protein S-Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S. Blood <b>83<\/b>, 683-690.","DOI":"10.1182\/blood.V83.3.683.bloodjournal833683"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Hayashi, T., Nishioka, J. and Suzuki, K. (1995) Molecular mechanism of dysfunctional protein S(Tokushima) (Lys155\u2192Glu) for the regulation of the blood coagulation system. Biochim. Biophys. Acta <b>1272<\/b>, 159-167.","DOI":"10.1016\/0925-4439(95)00081-X"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Tsuda, H., Noguchi, K., Oh, D., Bereczky, Z., Lee, L.H., Kang, D. <i>et al<\/i>. (2020) Racial differences in protein S-Tokushima and two protein C variants as genetic risk factors for venous thromboembolism. Res. Pract. Thromb. Haemost. <b>4<\/b>, 1295-1300.","DOI":"10.1002\/rth2.12440"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Saller, F., Brisset, A.C., Tchaikovski, S.N., Azevedo, M., Chrast, R., Fern\u00e1ndez, J.A. <i>et al<\/i>. (2009) Generation and phenotypic analysis of protein S-deficient mice. Blood <b>114<\/b>, 2307-2314.","DOI":"10.1182\/blood-2009-03-209031"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Nold, M.F., Nold-Petry, C.A., Fischer, D., Richter, B., Blaheta, R., Pfeilschifter, J. <i>et al<\/i>. (2007) Activated protein C downregulates p38 mitogen-activated protein kinase and improves clinical parameters in an in-vivo model of septic shock. Thromb. Haemost. <b>98<\/b>, 1118-1126.","DOI":"10.1160\/TH07-01-0052"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Uchiba, M., Okajima, K., Oike, Y., Ito, Y., Fukudome, K, Isobe, H. <i>et al<\/i>. (2004) Activated protein C induces endothelial cell proliferation by mitogen-activated protein kinase activation in vitro and angiogenesis in vivo. Circ. Res. <b>95<\/b>, 34-41.","DOI":"10.1161\/01.RES.0000133680.87668.FA"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Feistritzer, C. and Riewald, M. (2005) Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood <b>105<\/b>, 3178-3184.","DOI":"10.1182\/blood-2004-10-3985"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Healy, L.D., Puy, C., Fern\u00e1ndez, J.A., Mitrugno, A., Keshari, R.S., Taku, N.A. <i>et al<\/i>. (2017) Activated protein C inhibits neutrophil extracellular trap formation <i>in vitro<\/i> and activation <i>in vivo<\/i>. J. Biol. Chem. <b>292<\/b>, 8616-8629.","DOI":"10.1074\/jbc.M116.768309"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Gur-Cohen, S., Itkin, T., Chakrabarty, S., Graf, C., Kollet, O., Ludin, A. <i>et al<\/i>. (2015) PAR1 signaling regulates the retention and recruitment of EPCR expressing bone marrow hematopoietic stem cells. Nat. Med. <b>21<\/b>, 1307-1317.","DOI":"10.1038\/nm.3960"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Kurata, T., Hayashi, T., Yoshikawa, T., Okamoto, T., Yoshida, K., Iino, T. <i>et al<\/i>. (2010) Activated protein C stimulates osteoblast proliferation via endothelial protein C receptor. Thromb. Res. <b>125<\/b>, 184-191.","DOI":"10.1016\/j.thromres.2009.09.005"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Yoshida, K., Akita, N., Okamoto, T., Asanuma, K., Uchida, A., Sudo A. <i>et al<\/i>. (2018) Activated protein C suppresses osteoclast differentiation via endothelial protein C receptor, protease-activated receptor-1, sphingosine 1-phosphate receptor, and apolipoprotein E receptor 2. Thromb. Res. <b>163<\/b>, 30-40.","DOI":"10.1016\/j.thromres.2018.01.001"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Kondreddy, V., Wang, J., Keshava, S., Esmon, C.T., Rao, L.V.M. and Pendurthi, U.R. (2018). Factor VIIa induces anti-inflammatory signaling via EPCR and PAR1. Blood <b>131<\/b>, 2379-2392.","DOI":"10.1182\/blood-2017-10-813527"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Elphick, G.F., Sarangi, P.P., Hyun, Y.M., Hollenbaugh, J.A., Ayala, A., Biffl, W.L. <i>et al<\/i>. (2009) Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. Blood <b>113<\/b>, 4078-4085.","DOI":"10.1182\/blood-2008-09-180968"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Cao, C., Gao, Y., Li, Y., Antalis, T.M., Castellino, F.J. and Zhang, L. (2010) The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. J. Clin. Invest. <b>120<\/b>, 1971-1980.","DOI":"10.1172\/JCI40380"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Huckriede, J.B., Beurskens, D.M.H., Wildhagen, K.C.C.A., Reutelingsperger, C.P.M., Wichapong, K. and Nicolaes, G.A.F. (2023) Design and characterization of novel activated protein C variants for the proteolysis of cytotoxic extracellular histone H3. J. Thromb. Haemost. <b>21<\/b>, 3557-3567.","DOI":"10.1016\/j.jtha.2023.08.023"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Kokame, K., Zheng, X. and Sadler, J.E. (1998) Activation of thrombin-activatable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. J. Biol. Chem. <b>273<\/b>, 12135-12139.","DOI":"10.1074\/jbc.273.20.12135"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Mosnier, L.O. (2011) Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin. J. Biol. Chem. <b>286<\/b>, 502-510.","DOI":"10.1074\/jbc.M110.147959"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Plug, T. and Meijers, J.C.M. (2016) Structure-function relationships in thrombin-activatable fibrinolysis inhibitor. J. Thromb. Haemost. <b>14<\/b>, 633-644.","DOI":"10.1111\/jth.13261"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Shi, C.S., Shi, G.Y., Hsiao, H.M., Kao, Y.C., Kuo, K.L., Ma, C.Y. <i>et al<\/i>. (2008) Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood <b>112<\/b>, 3661-3670.","DOI":"10.1182\/blood-2008-03-142760"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Ma, C.Y., Chang, W.E., Shi, G.Y., Chang, B.Y., Cheng, S.E., Shih, Y.T. <i>et al<\/i>. (2015). Recombinant thrombomodulin inhibits lipopolysaccharide-induced inflammatory response by blocking the functions of CD14. J. Immunol<i>.<\/i> <b>194<\/b>, 1905-1915.","DOI":"10.4049\/jimmunol.1400923"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Abeyama, K., Stern, D.M., Ito, Y., Kawahara, K., Yoshimoto, Y., Tanaka, M. <i>et al<\/i>. (2005). The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J. Clin. Invest. <b>115<\/b>, 1267-1274.","DOI":"10.1172\/JCI200522782"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Ito, T., Kawahara, K., Okamoto, K., Yamada, S., Yasuda, M., Imaizumi, H. <i>et al<\/i>. (2008) Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler. Thromb. Vasc. Biol. <b>28<\/b>, 1825-1830.","DOI":"10.1161\/ATVBAHA.107.150631"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Shrestha, B., Ito, T., Kakuuchi, M., Totoki, T., Nagasato, T., Yamamoto, M. <i>et al<\/i>. (2019) Recombinant thrombomodulin suppresses histone-induced neutrophil extracellular trap formation. Front. Immunol. <b>10<\/b>, 2535.","DOI":"10.3389\/fimmu.2019.02535"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Lin, W.L., Chang, C.F., Shi, C.S., Shi, G.Y. and Wu, H.L. (2013) Recombinant lectin-like domain of thrombomodulin suppresses vascular inflammation by reducing leukocyte recruitment via interacting with Lewis Y on endothelial cells. Arterioscler. Thromb. Vasc. Biol. <b>33<\/b>, 2366-2373.","DOI":"10.1161\/ATVBAHA.113.301221"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Kawamoto, E., Nago, N., Okamoto, T., Gaowa, A., Masui-Ito, A., Sakakura, Y. <i>et al<\/i>. (2019) Anti-adhesive effects of human soluble thrombomodulin and its domains. Biochem. Biophys. Res. Commun. <b>511<\/b>, 312-317.","DOI":"10.1016\/j.bbrc.2019.02.041"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Ikezoe, T., Yang, J., Nishioka, C. and Yokoyama, A. (2015) Thrombomodulin alleviates murine GVHD in association with an increase in the proportion of regulatory T cells in the spleen. Bone Marrow Transplant. <b>50<\/b>, 113-120.","DOI":"10.1038\/bmt.2014.208"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Pan, B., Wang, X., Nishioka, C., Honda, G., Yokoyama, A., Zeng, L. <i>et al<\/i>. (2017) G-protein coupled receptor 15 mediates angiogenesis and cytoprotective function of thrombomodulin. Sci. Rep. <b>7<\/b>, 692.","DOI":"10.1038\/s41598-017-00781-w"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Suzuki, K., Nishioka, J. and Hashimoto, S. (1983) Protein C inhibitor: Purification from human plasma and characterization. J. Biol. Chem. <b>258<\/b>,163-168.","DOI":"10.1016\/S0021-9258(18)33235-6"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Toma, K., Yamamoto, S., Deyashiki Y. and Suzuki, K. (1987) Three-dimensional structure of protein C inhibitor predicted from structure of \u03b11-antitrypsin with computer graphics. Protein Eng. <b>1<\/b>, 471-475.","DOI":"10.1093\/protein\/1.6.471"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Suzuki, K., Deyashiki, Y., Nishioka, J., Kurachi, K., Akira, M., Yamamoto, S. <i>et al<\/i>. (1987) Characterization of a cDNA for human protein C inhibitor. A new member of the plasma serine protease inhibitor superfamily. J Biol. Chem. <b>262<\/b>, 611-616.","DOI":"10.1016\/S0021-9258(19)75827-X"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Rezaie, A.R., Cooper, S.T., Church, F.C. and Esmon, C.T. (1995) Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J. Biol. Chem. <b>270<\/b>, 25336-25339.","DOI":"10.1074\/jbc.270.43.25336"},{"key":"78","unstructured":"78) Minamikawa, K., Wada, H., Wakita, Y., Ohiwa, M., Tanigawa, M., Deguchi, K. <i>et al<\/i>. (1994) Increased activated protein C-protein C inhibitor complex levels in patients with pulmonary embolism. Thromb. Haemost. <b>71<\/b>, 192-194."},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Takagi, M., Wada, H., Mukai, K., Minamikawa, K., Wakita, Y., Deguchi, K. <i>et al<\/i>. (1999) Increased activated protein C: protein C inhibitor complex levels in patients with chronic renal failure on maintenance hemodialysis. Clin. Appl. Thromb. Hemost. <b>5<\/b>, 113-116.","DOI":"10.1177\/107602969900500207"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Watanabe, R., Wada, H., Sakakura, M., Mori, Y., Nakasaki, T., Okugawa, Y. <i>et al<\/i>. (2000) Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states. Am. J. Hematol. <b>65<\/b>, 35-40.","DOI":"10.1002\/1096-8652(200009)65:1<35::AID-AJH6>3.0.CO;2-1"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Wakita, T., Hayashi, T., Nishioka, J., Tamaru, H., Akita, N., Asanuma, K. <i>et al<\/i>. (2004) Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreased in renal cell carcinoma. Int. J. Cancer <b>108<\/b>, 516-523.","DOI":"10.1002\/ijc.11594"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Hamada, T., Kamada, H., Hayashi, T., Nishioka, J., Gabazza, E.C., Isaji, S. <i>et al<\/i>. (2008) Protein C inhibitor regulates hepatocyte growth factor activator- mediated liver regeneration in mice model. Gut <b>57<\/b>, 365-373.","DOI":"10.1136\/gut.2007.130153"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Suzuki, K. (2010) Hepatocyte growth factor activator (HGFA): its regulation by protein C inhibitor. FEBS J. <b>277<\/b>, 2223-2229.","DOI":"10.1111\/j.1742-4658.2010.07639.x"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Hayashi, T., Kume, M., Nishioka, J., Kamada, H., Gabazza, E.C., Ido, M. <i>et al<\/i>. (2004) Characterization of mice transgenic for a human protein C inhibitor gene, useful as <i>in vivo<\/i> models for the evaluation of the therapeutic effects of human activated protein C. J. Thromb. Haemost. <b>2<\/b>, 949-961.","DOI":"10.1111\/j.1538-7836.2004.00733.x"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Uhrin, P., Dewerchin, M., Hilpert, M., Chrenek, P., Sch\u04e7fer, C., Zechmeister-Machhart, M. <i>et al<\/i>. (2000) Disruption of the protein C inhibitor gene results in impaired spermatogenesis and male infertility. J. Clin. Invest. <b>106<\/b>, 1531-1539.","DOI":"10.1172\/JCI10768"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) Zheng, X., Geiger, M., Ecke, S., Bielek, E., Donner, P., Ebersp\u00e4cher, U. <i>et al<\/i>. (1994) Inhibition of acrosin by protein C inhibitor and localization of protein C inhibitor to spermatozoa. Am. J. Physiol. <b>267<\/b>, C466-C472.","DOI":"10.1152\/ajpcell.1994.267.2.C466"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Kise, H., Nishioka, J., Kawamura, J. and Suzuki, K. (1996) Characterization of semenogelin II, and its molecular interaction with prostate specific antigen and protein C inhibitor. Eur. J. Biochem. <b>238<\/b>, 88-96.","DOI":"10.1111\/j.1432-1033.1996.0088q.x"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Suzuki, K. (2008) The multi-functional serpin, protein C inhibitor: beyond thrombosis and hemostasis. J. Thromb. Haemost. <b>6<\/b>, 2017-2026.","DOI":"10.1111\/j.1538-7836.2008.03181.x"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Gomi, K., Zushi, M., Honda, G., Kawahara, S., Matsuzaki, O., Kanabayashi, T. <i>et al<\/i>. (1990) Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. Blood <b>75<\/b>, 1396-1399.","DOI":"10.1182\/blood.V75.7.1396.bloodjournal7571396"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Aoki, Y., Ohishi, R., Takei, R., Matsuzaki, O., Mohri, M., Saitoh K. <i>et al<\/i>. (1994) Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III. Thromb. Haemost. <b>71<\/b>, 452-455.","DOI":"10.1055\/s-0038-1642459"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Takehara, K., Murakami, T., Kuwahara-Arai, K., Iba, T., Nagaoka, I. and Sakamoto, K. (2017) Evaluation of the effect of recombinant thrombomodulin on a lipopolysaccharide-induced murine sepsis model. Exp. Ther. Med. <b>13<\/b>, 2969-2974.","DOI":"10.3892\/etm.2017.4308"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Shirai, Y., Uwagawa, T., Shiba, H., Shimada, Y., Horiuchi, T., Saito, N. <i>et al<\/i>. (2017) Recombinant thrombomodulin suppresses tumor growth of pancreatic cancer by blocking thrombin-induced PAR1 and NF-\u03baB activation. Surgery <b>161<\/b>, 1675-1682.","DOI":"10.1016\/j.surg.2016.12.008"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) Hosaka, Y., Higuchi, T., Tsumagari, M. and Ishii, H. (2000) Inhibition of invasion and experimental metastasis of murine melanoma cells by human soluble thrombomodulin. Cancer Lett. <b>161<\/b>, 231-240.","DOI":"10.1016\/S0304-3835(00)00617-0"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Bazzi, Z.A., Lanoue, D., El-Youssef, M., Romagnuolo, R., Tubman, J., Cavallo-Medved, D. <i>et al<\/i>. (2016) Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis. BMC Cancer <b>16<\/b>, 328.","DOI":"10.1186\/s12885-016-2359-1"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Huang, Y.H., I, C.C., Kuo, C.H., Hsu, Y.Y., Lee, F.T., Shi, G.Y. <i>et al<\/i>. (2015) Thrombomodulin promotes corneal epithelial wound healing. PLoS One <b>10<\/b>, e0122491.","DOI":"10.1371\/journal.pone.0122491"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Wei, H.J., Li, Y.H., Shi, G.Y., Liu, S.L., Chang, P.C., Kuo, C.H. <i>et al<\/i>. (2011) Thrombomodulin domains attenuate atherosclerosis by inhibiting thrombin-induced endothelial cell activation. Cardiovasc. Res. <b>92<\/b>, 317-327.","DOI":"10.1093\/cvr\/cvr220"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) Nakayama, H., Inada, H., Inukai, T., Kondo, K., Hirai, K., Tsutsumi, T. <i>et al<\/i>. (2022) Recombinant human soluble thrombomodulin suppresses arteritis in a mouse model of Kawasaki disease. J. Vasc. Res. <b>59<\/b>, 176-188.","DOI":"10.1159\/000520717"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Ikezoe T, Yang J, Nishioka C, Pan B, Xu K, Furihata M <i>et al<\/i>. (2017) The fifth epidermal growth factor-like region of thrombomodulin exerts cytoprotective function and prevents SOS in a murine model. Bone Marrow Transplant. <b>52<\/b>, 73-79.","DOI":"10.1038\/bmt.2016.195"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Ikezoe, T., Yang, J., Nishioka, C., Umezawa, K. and Yokoyama, A. (2017) Thrombomodulin blocks calcineurin inhibitor-induced vascular permeability via inhibition of Src\/VE-cadherin axis. Bone Marrow Transplant. <b>52<\/b>, 245-251.","DOI":"10.1038\/bmt.2016.241"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100) Yang, S.M., Ka, S.M., Wu, H.L., Yeh, Y.C., Kuo, C.H., Hua, K.F. <i>et al<\/i>. (2014) Thrombomodulin domain 1 ameliorates diabetic nephropathy in mice via anti-NF-\u03baB\/NLRP3 inflammasome-mediated inflammation, enhancement of NRF2 antioxidant activity and inhibition of apoptosis. Diabetologia <b>57<\/b>, 424-434.","DOI":"10.1007\/s00125-013-3115-6"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101) Sharfuddin, A.A., Sandoval, R.M., Berg, D.T., McDougal, G.E., Campos, S.B., Phillips, C.L. <i>et al<\/i>. (2009) Soluble thrombomodulin protects ischemic kidneys. J. Am. Soc. Nephrol. <b>20<\/b>, 524-534.","DOI":"10.1681\/ASN.2008060593"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102) Fujii, T., Kuriyama, N., Hayasaki, A., Iizawa, Y., Tanemura, A., Kato, H. <i>et al<\/i>. (2018) Recombinant human soluble thrombomodulin attenuates hepatic ischemia and\/or reperfusion injury by inhibiting leukocyte accumulation in mice with normal and fatty liver. Transplant. Proc. <b>50<\/b>, 2807-2814.","DOI":"10.1016\/j.transproceed.2018.03.044"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103) Hirao, S., Minakata, K., Masumoto, H., Yamazaki, K., Ikeda, T., Minatoya, K. <i>et al<\/i>. (2017). Recombinant human soluble thrombomodulin prevents acute lung injury in a rat cardiopulmonary bypass model. J. Thorac. Cardiovasc. Surg. <b>154<\/b>, 1973-1983.e1.","DOI":"10.1016\/j.jtcvs.2017.05.051"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104) Shin, M., Hino, H., Tamura, M., Ishizuka, B., Tanaka, M., Suzuki, N. <i>et al<\/i>. (2014) Thrombomodulin improves maternal and fetal conditions in an experimental pre-eclampsia rat model. J. Obstet. Gynaecol. Res. <b>40<\/b>, 1226-1234.","DOI":"10.1111\/jog.12323"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105) Fujiwara, K., Kobayashi, T., Fujimoto, H., Nakahara, H., D&apos;Alessandro-Gabazza, C.N., Hinneh, J.A. <i>et al<\/i>. (2017) Inhibition of cell apoptosis and amelioration of pulmonary fibrosis by thrombomodulin. Am. J. Pathol. <b>187<\/b>, 2312-2322.","DOI":"10.1016\/j.ajpath.2017.06.013"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106) Takagi, T., Taguchi, O., Toda, M., Ruiz, D.B., Bernabe, P.G., D&apos;Alessandro-Gabazza, C.N. <i>et al<\/i>. (2011) Inhibition of allergic bronchial asthma by thrombomodulin is mediated by dendritic cells. Am. J. Respir. Crit. Care Med. <b>183<\/b>, 31-42.","DOI":"10.1164\/rccm.201001-0107OC"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107) Saito, H., Maruyama, I., Shimazaki, S., Yamamoto, Y., Aikawa, N., Ohno, R. <i>et al<\/i>. (2007) Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized,double-blind clinical trial. J. Thromb. Haemost. <b>5<\/b>, 31-41.","DOI":"10.1111\/j.1538-7836.2006.02267.x"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108) Asakura, H., Takahashi, H., Tsuji, H., Matsushita, T., Ninomiya, H., Honda, G. <i>et al<\/i>. (2014) Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - Safety and efficacy in 1,032 patients with hematologic malignancy. Thromb. Res. <b>133<\/b>, 364-370.","DOI":"10.1016\/j.thromres.2013.12.033"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109) Eguchi, Y., Gando, S., Ishikura, H., Saitoh, D., Mimuro, J., Takahashi, H. <i>et al<\/i>. (2014) Post-marketing surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation. J. Intensive Care <b>2<\/b>, 30-39.","DOI":"10.1186\/2052-0492-2-30"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110) Matsushita, T., Watanabe, J., Honda, G., Mimuro, J., Takahashi, H., Tsuji, H. <i>et al<\/i>. (2014) Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort. Thromb. Res. <b>133<\/b>, 772-781.","DOI":"10.1016\/j.thromres.2014.02.025"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111) Shirahata, A., Mimuro, J., Takahashi, H., Tsuji, H., Kitajima, I., Matsushita, T. <i>et al<\/i>. (2014) Postmarketing surveillance of recombinant human soluble thrombomodulin (thrombomodulin \u03b1) in pediatric patients with disseminated intravascular coagulation. Clin. Appl. Thromb. Hemost. <b>20<\/b>, 465-472.","DOI":"10.1177\/1076029614523490"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112) Wada, H., Japanese Society of Thrombosis Hemostasis\/DIC subcommittee, Okamoto, K., Iba, T., Kushimoto, S., Kawasugi, K. <i>et al<\/i>. (2014) Addition of recommendations for the use of recombinant human thrombomodulin to the &quot;Expert consensus for the treatment of disseminated intravascular coagulation in Japan&quot;. Thromb. Res. <b>134<\/b>, 924-925.","DOI":"10.1016\/j.thromres.2014.07.033"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113) Wada, H., Asakura, H., Okamoto, K., Iba, T., Uchiyama, T., Kawasugi, K. <i>et al<\/i>. (2010) Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb. Res. <b>125<\/b>, 6-11.","DOI":"10.1016\/j.thromres.2009.08.017"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114) Yoshimura, J., Yamakawa, K., Ogura, H., Umemura, Y., Takahashi, H., Morikawa, M. <i>et al<\/i>. (2015) Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Crit. Care <b>19<\/b>, 78.","DOI":"10.1186\/s13054-015-0810-3"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115) Vincent, J.L., Francois, B., Zabolotskikh, I., Daga, M.K., Lascarrou, J.B., Kirov, M.Y. <i>et al<\/i>. (2019) Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial. JAMA <b>321<\/b>, 1993-2002.","DOI":"10.1001\/jama.2019.5358"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116) Yamakawa, K., Levy, J.H. and Iba, T. (2019) Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis. Crit. Care <b>23<\/b>, 302.","DOI":"10.1186\/s13054-019-2587-2"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117) Matsushita, T., Watanabe, J., Honda, G., Mimuro, J., Takahashi, H., Tsuji, H. <i>et al<\/i>. (2014) Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort. Thromb. Res. <b>133<\/b>, 772-781.","DOI":"10.1016\/j.thromres.2014.02.025"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118) Takezako, N., Sekiguchi, N., Nagata, A., Homma, C., Takezako, Y., Noto, S. <i>et al<\/i>. (2015) Recombinant human thrombomodulin in the treatment of acute myeloid leukemia patients complicated by disseminated intravascular coagulation: retrospective analysis of outcomes between patients treated with heparin and recombinant human thrombomodulin therapy. Thromb. Res. <b>136<\/b>, 20-23.","DOI":"10.1016\/j.thromres.2015.03.029"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119) Ikezoe, T., Takeuchi, A., Isaka, M., Arakawa, Y., Iwabu, N., Kin, T. <i>et al<\/i>. (2012) Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation. Leuk. Res. <b>36<\/b>, 1398-1402.","DOI":"10.1016\/j.leukres.2012.08.012"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120) Kawano, N., Fukatsu, M., Yamakawa, K., Seki, Y., Wada, H., Okamoto, K. <i>et al<\/i>. (2024) A systematic review and meta-analysis of recombinant human soluble thrombomodulin for the treatment of DIC associated with hematological malignancies. Int. J. Hematol. <b>119<\/b>, 416-425.","DOI":"10.1007\/s12185-023-03704-w"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121) Tamura, K., Saito, H., Asakura, H., Okamoto, K., Tagawa, J., Hayakawa, T. <i>et al<\/i>. (2015) Recombinant human soluble thrombomodulin (thrombomodulin alfa) to treat disseminated intravascular coagulation in solid tumors: results of a one-arm prospective trial. Int. J. Clin. Oncol. <b>20<\/b>, 821-828.","DOI":"10.1007\/s10147-014-0768-1"},{"key":"122","doi-asserted-by":"crossref","unstructured":"122) Ouchi, K., Takahashi, S., Chikamatsu, S., Ito, S., Takahashi, Y., Kawai, S. <i>et al<\/i>. (2018) Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors. Int. J. Clin. Oncol. <b>23<\/b>, 790-798.","DOI":"10.1007\/s10147-018-1261-z"},{"key":"123","unstructured":"123) Yamakawa, K., Ohbe, H., Taniguchi, K., Matsui, H., Fushimi, K. and Yasunaga, H. (2020) Time trends of the outcomes and treatment options for disseminated intravascular coagulation: a nationwide observational study in Japan. JMA J. <b>3<\/b>, 313-320."},{"key":"124","doi-asserted-by":"crossref","unstructured":"124) Miura, F., Okamoto, K., Takada, T., Strasberg, S.M., Asbun, H.J., Pitt, H.A. <i>et al<\/i>. (2018) Tokyo guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis. J. Hepatobiliary Pancreat. Sci. <b>25<\/b>, 31-40.","DOI":"10.1002\/jhbp.509"},{"key":"125","unstructured":"125) Suzuki, K. (2024) Thrombomodulin. Thrombosis Medicine <b>14<\/b>, 198-208 (in Japanese)."}],"container-title":["Proceedings of the Japan Academy, Series B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/pjab\/101\/2\/101_pjab.101.006\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T23:27:23Z","timestamp":1739575643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/pjab\/101\/2\/101_pjab.101.006\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":125,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2183\/pjab.101.006","relation":{},"ISSN":["0386-2208","1349-2896"],"issn-type":[{"value":"0386-2208","type":"print"},{"value":"1349-2896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"pjab.101.006"}}